1421372-34-0

Basic information

• Product Name: N- (4-fluoro-2-methoxy-5-nitrophenyl)-4-(1H-indol-3-yl)pyrimidin-2-amine
• Synonyms: N- (4-fluoro-2-methoxy-5-nitrophenyl)-4-(1H-indol-3-yl)pyrimidin-2-amine
• CAS NO: 1421372-34-0
• Molecular Weight: 379.35
• Mol File: 1421372-34-0.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 655.2±65.0 °C(Predicted)
• Density: 1.460±0.06 g/cm3(Predicted)
• CAS DataBase Reference: N- (4-fluoro-2-methoxy-5-nitrophenyl)-4-(1H-indol-3-yl)pyrimidin-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: N- (4-fluoro-2-methoxy-5-nitrophenyl)-4-(1H-indol-3-yl)pyrimidin-2-amine(1421372-34-0)
• EPA Substance Registry System: N- (4-fluoro-2-methoxy-5-nitrophenyl)-4-(1H-indol-3-yl)pyrimidin-2-amine(1421372-34-0)

Safety Data

• Hazardous Substances Data: 1421372-34-0(Hazardous Substances Data)

Upstream product

• 450-91-9 4-fluoro-2-methoxyaniline 
• 120-72-9 indole 
• 945016-63-7 3-(2-chloro-pyrimidin-4-yl)-1H-indole 
• 1075705-01-9 4-fluoro-2-methoxy-5-nitro-phenylamine 

Downstream Products

• 2129998-32-7 C₂₇H₂₅⁽²⁾H₆N₇O₂*CH₄O₃S 

Relevant articles and documents

Compound, containing conjugated dienamide structure, preparation method, pharmaceutical composition and application thereof

The invention relates to a compound containing a conjugated allene amide structure and a preparation method, a medicine composition and application thereof, in particular to a compound containing a conjugated allene amide structure shown in a formula (I), and a preparation method, a medicine composition and application thereof in preparation of an EGFR (epidermal growth factor receptor) inhibitoror a medicine for preventing and/or treating EGFR-related diseases, especially cancers. (The formula (I) is shown in the description.).

2 - (2,Anilino) pyrimidine compound and application thereof (by machine translation)

The invention relates to certain 2 - (2,anilino) pyrimidine compounds represented by the following formula I and application thereof. These compounds or salts thereof show a higher inhibition of EGFR than wild-type EGFR in the form of an activated or drug resistant mutant. Since the toxicity associated with the wild-type EGFR inhibition is reduced, it is expected that such a compound or salt thereof has excellent pharmacodynamic properties, higher metabolic stability, better blood-brain barrier permeability, and more suitable for use as a therapeutic agent, particularly for the treatment of cancer. , These compounds or salts thereof can be used to prepare EGFR-mediated diseases, in particular non-small cell lung cancer, for the treatment of certain mutated forms. (by machine translation)

Phenylaminopyrimidine derivative used as ERK inhibitor

The invention specifically relates to a novel phenylaminopyrimidine derivative used as an ERK inhibitor and a pharmaceutically acceptable salt thereof, belonging to the field of medical chemistry. Theinvention specifically discloses a compound as shown in a formula I which is described in the specification and a pharmaceutically acceptable salt and a pharmaceutical composition thereof, and a method for applying the compound to treatment of diseases resulting from ERK inhibition.